主页 > 医药生命 >
【商业翻译】Guidelines On Skin Reactions To New Class O
1.保证质量。
2.本星期三（5.30）晚上10点前交稿。
3.格式见置顶的文摘编译格式：
http://www.dxy.cn/bbs/post/view?bid=116&id=8600034&sty=1&tpg=1&age=0
4.稿酬按医师报标准。
5.为保证翻译质量起见，在本版得分超过15分以上的战友方可认领。
6.每位战友最多认领2篇，编译群战友可根据自己的专业和精力，最多认领3篇。
7.作者统一署名为"丁香"
8.文中出现的杂志名称用原文，无需翻译。 本人已认领该文编译，24小时后若未提交译文，请其他战友自由认领 中文字1198
Guidelines On Skin Reactions To New Class Of Cancer Drugs
Main Category: Cancer / Oncology News
Article Date: 28 May 2007 - 18:00 PDT
新型肿瘤药物皮肤反应指南
Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach - usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."
按照The Oncologist五月刊的一篇文章所说，一种有效的新型抗癌药物经常都会产生皮肤反应，但是这是可控的，治疗方法简单而合理：通常不需要减少剂量或者中断化疗。
The special article presents the first recommendations on skin reactions to the new drugs, called Epidermal Growth Factor Receptor Inhibitors (EGFRIs). The guidelines were developed at an international multidisciplinary meeting, including medical oncologists, dermatologists, nurses, and pharmacists. "One important goal is to ensure that healthcare professionals and patients see EGFRI-associated dermatologic toxicity as manageable, thereby optimizing clinical benefit from continued and uninterrupted use of EGFRIs when possible," according to lead author Dr. Thomas J. Lynch, Jr., of Massachusetts General Hospital, Boston.
该文章对这种称为表皮生长因子受体抑制剂（EGFRIs）的新药所产生的皮肤反应提出了首个指南。该指南产生于一个国际性的多学科会议，与会人员包括医学肿瘤学家、皮肤病学家、护士和药剂师。按照该文第一作者、波士顿麻省总医院的Thomas J. Lynch, Jr.博士所说：“一个重要的目标是使医护人员和病人确信EGFRI相关的皮肤毒性是可控的，因此，在可行的情况下坚持持续使用EGFRIs，使临床效果最好。”
Treatment with EGFRIs has been shown to improve survival in patients with several types of cancer, including lung, pancreatic, and colorectal cancers. The drugs - including erlotinib (Tarceva), cetuximab (Erbitux), and panitumumab (Vectibix) - work by interfering with cell-signaling abnormalities that contribute to cancer development and growth.
用EGFRIs治疗可以改善多种肿瘤病人的生存率，包括肺部肿瘤，胰腺肿瘤和结直肠肿瘤。这类药物包括erlotinib (Tarceva)、cetuximab (Erbitux)和panitumumab (Vectibix)，其作用在于阻碍细胞信号异常，而信号异常在肿瘤发生和生长中是有着重要作用的。
Unfortunately, the EGFRIs carry a substantial risk of skin reactions - more than half of treated patients have some type of skin toxicity, most commonly an acne-like rash. The reactions most likely occur because the receptor blocked by the drugs also performs key functions in normal skin. There is even evidence that the rash may be a sign that EGFRI anti-cancer treatment is working - in some studies, patients with more severe skin reactions had better survival. The skin reactions are rarely so severe that the dosage is reduced or treatment stopped. Until recently, there was no strong scientific data to guide the treatment of skin reactions to EGFRIs.
不幸的是，EFGRIs的皮肤反应风险很高，该类药物治疗的病人超过一半出现不同程度的皮肤毒性，最常见的为痤疮样皮疹。这些反应的出现很可能是因为，被该类药物阻断的受体在正常皮肤中也起着重要作用。而且甚至有证据表明，皮疹可能是EGFRI抗癌治疗有效的一个标致：在一些研究中，皮肤反应越强的病人生存率更高。一般药物的皮肤反应很少会如此强烈，因此医生们通常都会减少该药剂量或者停止治疗。直到现在，都没有明确的科学数据对EGFRIs产生的皮肤反应进行治疗指引。
To address this issue, the authors propose a simple system for classification and treatment of skin reactions. To start, all patients receiving EGFRIs are advised to use a moisturizer and protect against exposure to sunlight - the rash may be more severe in sun-exposed areas.
作者们在阐述该文时，提出了一个皮肤反应分类的简单系统及治疗方案。首先，所有接受EGFRIs治疗的病人都被建议使用增湿机，同时避免阳光暴露：阳光暴露区域的皮疹可能会更严重。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-20 17:11
医学,生命科学网